| 000 | 00987 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513042019.0 | ||
| 264 | 0 | _c19950607 | |
| 008 | 199506s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(95)92035-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEvans, D I | |
| 245 | 0 | 0 |
_aVirus infection and clotting factor concentrates. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMay 1995 |
||
| 300 |
_a1247-8 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aDrug Contamination _xprevention & control |
| 650 | 0 | 4 |
_aErythema Infectiosum _xtransmission |
| 650 | 0 | 4 |
_aFactor VIII _xtherapeutic use |
| 650 | 0 | 4 |
_aHemophilia A _xtherapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPlasma _xvirology |
| 650 | 0 | 4 |
_aVirus Diseases _xtransmission |
| 773 | 0 |
_tLancet (London, England) _gvol. 345 _gno. 8959 _gp. 1247-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(95)92035-8 _zAvailable from publisher's website |
| 999 |
_c7738705 _d7738705 |
||